Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Not for use in diagnostic procedures, human use, or veterinary use
It is the first FDA- approved drug since 2017 for chronic weight management in overweight adults with obesity
Semaglutide was administered subcutaneously to the subjects once per week at doses that were eventually increased to 1.0 mg
Medicare Utilization of GLP-1s Rises with Broader Indications Beyond Obesity Since Medicare does not cover anti obesity drugs when prescribed solely for weight management, utilization of weight loss indicated GLP-1s historically lagged behind their use in commercial markets
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management
A study of 559 Blue Sky MD patients showed an average weight loss of 13% in just 12 weeksthats nearly 30 pounds in just 3 months and more than double what patients see with Wegovy alone.* Individual results may vary
:max_bytes(150000):strip_icc()/VWH-MiraNorian-WeightLossDrugUpdate-4000x2700-c813fa5051604eec9c136047fb44d23a.png)
